Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry

Journal of Hepatology

Volumn 57, Issue 5, 2012, Pages 953-959

  Brown, Robert S ^a   Verna, Elizabeth C ^a   Pereira, Marcus R ^a   Tilson, Hugh H ^b   Aguilar, Christopher ^c   Leu, Cheng Shiun ^d   Buti, Maria ^e   Fagan, Elizabeth A ^c  

^a NewYork Presbyterian Hospital   (United States)

^b IL   (United States)

^c GILEAD SCIENCES   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiretroviral Pregnancy Registry; Birth defects; Hepatitis B

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIRTH DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENINE; ADULT; ANTIVIRAL AGENTS; CONGENITAL ABNORMALITIES; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; PHOSPHOROUS ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84867579021     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.06.031     Document Type: Article

References (39)

1. J.E. Maynard Hepatitis B: global importance and need for control Vaccine 8 Suppl. 1990 S18 S20 discussion S21-13
2. R.P. Beasley, L.Y. Hwang, C.C. Lin, M.L. Leu, C.E. Stevens, and W. Szmuness Incidence of hepatitis B virus infections in preschool children in Taiwan J Infect Dis 146 1982 198 204
3. M.J. Alter, S.C. Hadler, H.S. Margolis, W.J. Alexander, P.Y. Hu, and F.N. Judson The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies JAMA 263 1990 1218 1222
4. C.E. Stevens, R.P. Beasley, J. Tsui, and W.C. Lee Vertical transmission of hepatitis B antigen in Taiwan N Engl J Med 292 1975 771 774
5. A.S. Lok, C.L. Lai, P.C. Wu, E.K. Leung, and T.S. Lam Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection Gastroenterology 92 1987 1839 1843
6. A.S. Lok, and C.L. Lai A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children Hepatology 8 1988 1130 1133
7. Y.F. Liaw, C.M. Chu, D.Y. Lin, I.S. Sheen, C.Y. Yang, and M.J. Huang Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma J Med Virol 13 1984 385 391
8. C.E. Stevens, P.T. Toy, M.J. Tong, P.E. Taylor, G.N. Vyas, and P.V. Nair Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization JAMA 253 1985 1740 1745
9. E. Wiseman, M.A. Fraser, S. Holden, A. Glass, B.L. Kidson, and L.G. Heron Perinatal transmission of hepatitis B virus: an Australian experience Med J Aust 190 2009 489 492
10. R.D. Burk, L.Y. Hwang, G.Y. Ho, D.A. Shafritz, and R.P. Beasley Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load J Infect Dis 170 1994 1418 1423
11. X.M. Li, M.F. Shi, Y.B. Yang, Z.J. Shi, H.Y. Hou, and H.M. Shen Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection World J Gastroenterol 10 2004 3215 3217
12. H. Zou, Y. Chen, Z. Duan, H. Zhang, and C. Pan Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers J Viral Hepat 19 2012 e18 25
13. Z. Shi, Y. Yang, L. Ma, X. Li, and A. Schreiber Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis Obstet Gynecol 116 2010 147 159
14. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
15. D.J. Tenney, R.E. Rose, C.J. Baldick, K.A. Pokornowski, B.J. Eggers, and J. Fang Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
16. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, and M. Rizzetto Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 2006 1743 1751
17. T.T. Chang, Y.F. Liaw, S.S. Wu, E. Schiff, K.H. Han, and C.L. Lai Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
18. E.R. Schiff, S.S. Lee, Y.C. Chao, S. Kew Yoon, F. Bessone, and S.S. Wu Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B Clin Gastroenterol Hepatol 9 2011 274 276
19. M.A. Thompson, J.A. Aberg, P. Cahn, J.S. Montaner, G. Rizzardini, and A. Telenti Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel JAMA 304 2010 321 333
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http:// wwwaidsinfonihgov/ContentFiles/AdultandAdolescentGLpdf. [Accessed June 27, 2011].
21. F. Garcia, E. de Lazzari, M. Plana, P. Castro, G. Mestre, and M. Nomdedeu Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count J Acquir Immune Defic Syndr 36 2004 702 713
22. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-299.
23. A.I. van Sighem, L.A. Gras, P. Reiss, K. Brinkman, and F. de Wolf Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals AIDS 24 2010 1527 1535
24. W.M. El-Sadr, J.D. Lundgren, J.D. Neaton, F. Gordin, D. Abrams, and R.C. Arduino CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 355 2006 2283 2296
25. J.V. Baker, G. Peng, J. Rapkin, D.I. Abrams, M.J. Silverberg, and R.D. MacArthur CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection AIDS 22 2008 841 848
26. M. Bruyand, R. Thiebaut, S. Lawson-Ayayi, P. Joly, A.J. Sasco, and P. Mercie Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort Clin Infect Dis 49 2009 1109 1116
27. R. Bunnell, J.P. Ekwaru, P. Solberg, N. Wamai, W. Bikaako-Kajura, and W. Were Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda AIDS 20 2006 85 92
28. J. Castilla, J. Del Romero, V. Hernando, B. Marincovich, S. Garcia, and C. Rodriguez Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV J Acquir Immune Defic Syndr 40 2005 96 101
29. P.M. Garcia, L.A. Kalish, J. Pitt, H. Minkoff, T.C. Quinn, and S.K. Burchett Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group N Engl J Med 341 1999 394 402
30. L. Mofenson, A.W. Taylor, M. Rogers, M. Campsmith, N.M. Ruffo, and J. Clark Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005 MMWR Morb Mortal Wkly Rep 55 2006 592 597
31. International APRSCAPR, Interim Report for 1 January 1989 through 31 January 2011. Wilmington NRC, www.APRegistry.com. CAfU.
32. A. Correa, J.D. Cragan, J.E. Kucik, C.J. Alverson, S.M. Gilboa, and R. Balakrishnan Reporting birth defects surveillance data 1968-2003 Birth Defects Res A Clin Mol Teratol 79 2007 65 186
33. D. Patel, C. Thorne, S. Fiore, and M.L. Newell Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 40 2005 116 118
34. C.L. Townsend, B.A. Willey, M. Cortina-Borja, C.S. Peckham, and P.A. Tookey Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007 AIDS 23 2009 519 524
35. A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, and E.R. Schiff Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
36. E.J. Heathcote, P. Marcellin, M. Buti, E. Gane, R.A. De Man, and Z. Krastev Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
37. A. Vigano, S. Mora, V. Giacomet, S. Stucchi, V. Manfredini, and C. Gabiano In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers Antivir Ther 16 2011 1259 1266
38. D. Nurutdinova, N.F. Onen, E. Hayes, K. Mondy, and E.T. Overton Adverse effects of tenofovir use in HIV-infected pregnant women and their infants Ann Pharmacother 42 2008 1581 1585
39. G.K. Siberry, P.L. Williams, H. Mendez, G.R. Seage 3rd, D.L. Jacobson, and R. Hazra Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants AIDS 26 2012 1151 1159